Trial Profile
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Calcium gluconate (Primary) ; Colecalciferol (Primary) ; Zoledronic acid (Primary)
- Indications Male osteoporosis
- Focus Therapeutic Use
- 23 Oct 2020 Status changed from active, no longer recruiting to discontinued.
- 01 May 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 01 May 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.